Numinus Wellness (LR23) Stock Overview
Provides psychedelic-assisted therapy training, lab testing, and psychotherapy services in Canada and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
LR23 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Numinus Wellness Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.03 |
| 52 Week High | CA$0.084 |
| 52 Week Low | CA$0.021 |
| Beta | 2.49 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| LR23 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 2.5% |
| 1Y | n/a | 24.2% | 8.8% |
Return vs Industry: Insufficient data to determine how LR23 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LR23 performed against the German Market.
Price Volatility
| LR23 volatility | |
|---|---|
| LR23 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 13.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: LR23's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine LR23's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Michael Tan | www.numinusnetwork.com |
Numinus Wellness Inc. provides psychedelic-assisted psychotherapy products and services in Canada and the United States. The company operates through Clinical Research Operations, Canadian Clinic Network, and U.S Clinic Network segments. The Clinical Research Operations segment offers clinical research management services to academic institutions and biotechnology companies.
Numinus Wellness Inc. Fundamentals Summary
| LR23 fundamental statistics | |
|---|---|
| Market cap | €10.74m |
| Earnings (TTM) | -€17.00m |
| Revenue (TTM) | €14.99m |
Is LR23 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LR23 income statement (TTM) | |
|---|---|
| Revenue | CA$22.48m |
| Cost of Revenue | CA$15.68m |
| Gross Profit | CA$6.80m |
| Other Expenses | CA$32.31m |
| Earnings | -CA$25.51m |
Last Reported Earnings
May 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.079 |
| Gross Margin | 30.27% |
| Net Profit Margin | -113.45% |
| Debt/Equity Ratio | 35.4% |
How did LR23 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/02 18:12 |
| End of Day Share Price | 2024/12/03 00:00 |
| Earnings | 2024/05/31 |
| Annual Earnings | 2023/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Numinus Wellness Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Maxim Group |
| Michael Okunewitch | Maxim Group |